Sofie W.
- Country
- The Netherlands
- Department
- Netherlands Cancer Institute
Research Overview
- Efficacy Comparison of Nivolumab-Ipilimumab Versus Immune Checkpoint Inhibitor-VEGFR TKI Combinations in Untreated Metastatic Renal Cell Carcinoma
- Phase 3 Evaluation of Fianlimab and Cemiplimab Versus Pembrolizumab in Treatment-Naïve Unresectable Locally Advanced or Metastatic Melanoma
- Phase 1/2a Study of Relatlimab and Nivolumab in Advanced Solid Tumors: Safety, Tolerability, and Efficacy Evaluation
Data & Insights
Has run more than one trial at 26 of 207 partner sites.
Specializations
Oncology Focus
This investigator specializes in advanced melanoma treatment, with particular emphasis on exploring innovative therapeutic approaches for patients with unresectable locally advanced or metastatic disease.
- Advanced Skin Cancer Management
- Metastatic Melanoma Treatment
- Immunotherapy Research
The investigator's work centers on evaluating novel therapeutic combinations to enhance treatment outcomes in melanoma patients.
Immunotherapy Expertise
The investigator focuses on combination immunotherapy approaches, investigating novel therapeutic agents for improving patient outcomes in advanced melanoma treatment.
- Combination Therapy Development
- Treatment Response Assessment
- Advanced Cancer Care
Their research explores innovative immunotherapy combinations for previously untreated melanoma patients.
Clinical Assessment
The investigator specializes in evaluating disease progression and treatment effectiveness in advanced melanoma cases, with expertise in survival outcomes assessment.
- Treatment Response Monitoring
- Disease Progression Assessment
- Patient Outcome Evaluation
Their work includes comprehensive evaluation of therapeutic interventions in advanced melanoma settings.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.